Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) PT at $35.14

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $35.1364.

A number of analysts have issued reports on the stock. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. HC Wainwright raised their price objective on shares of Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Citigroup lifted their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st.

Roivant Sciences Trading Up 0.2%

ROIV stock opened at $36.36 on Tuesday. The company has a market capitalization of $26.26 billion, a PE ratio of -68.60 and a beta of 1.12. Roivant Sciences has a 12-month low of $11.60 and a 12-month high of $37.97. The business’s fifty day moving average price is $34.74 and its 200 day moving average price is $30.59.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. Research analysts predict that Roivant Sciences will post -2 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Monday, July 27th. The stock was sold at an average price of $34.95, for a total value of $6,990,000.00. Following the sale, the chief executive officer directly owned 1,613,063 shares in the company, valued at approximately $56,376,551.85. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction on Friday, August 21st. The shares were sold at an average price of $36.48, for a total value of $5,280,698.88. Following the completion of the transaction, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $679,649,358.72. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,855,913 shares of company stock valued at $100,107,258 in the last three months. 8.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in ROIV. Pictet Asset Management Holding SA lifted its position in shares of Roivant Sciences by 790.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after purchasing an additional 2,052,693 shares during the last quarter. Vanguard Group Inc. increased its holdings in Roivant Sciences by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock valued at $912,681,000 after buying an additional 3,254,113 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Roivant Sciences by 90.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company’s stock valued at $1,746,000 after buying an additional 38,354 shares in the last quarter. Nicholas Investment Partners LP raised its stake in Roivant Sciences by 13.9% in the fourth quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company’s stock valued at $6,073,000 after buying an additional 34,235 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in Roivant Sciences in the fourth quarter valued at $76,272,000. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.